文献速递胸部肿瘤

奥希替尼联合赛沃替尼治疗一线奥希替尼进展后EGFR突变伴MET扩增晚期NSCLC:临床结局、安全性与生物标志物分析

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
PubMed 文献 · J Thorac Oncol · 2025-10-21

ORCHARD研究报道奥希替尼联合赛沃替尼模块结果。32例一线奥希替尼进展后MET扩增的EGFR突变晚期NSCLC患者接受联合治疗,确认ORR为47%(80%CI 34-60),中位PFS 7.6个月,中位OS 20.7个月,安全性可控。

要点

  • 一线奥希替尼进展后MET扩增患者,奥希替尼联合赛沃替尼确认ORR达47%。
  • 中位PFS 7.6个月,中位DOR 14.5个月,中位OS 20.7个月。
  • MET基因拷贝数≥10较<10者ORR有升高趋势,安全性可控。

核心结论

  • 奥希替尼联合赛沃替尼在一线奥希替尼进展后EGFR突变伴MET扩增晚期NSCLC中显示令人鼓舞的临床获益,安全性符合各药已知特征。

研究设计与样本

  • ORCHARD(NCT03944772)研究为开放标签模块化研究,本模块纳入32例经一线奥希替尼进展后活检NGS确认MET基因扩增(MET拷贝数/肿瘤倍性≥4)的EGFR突变晚期NSCLC患者。
  • 主要终点为研究者评估的客观缓解率,次要终点包括无进展生存期、缓解持续时间、总生存期和安全性。
  • 探索性分析评估基线分子改变与ORR的相关性。

主要发现

  • 确认ORR为47%(80%CI 34-60)。
  • 中位DOR为14.5个月(95%CI 5.6-18.7),中位PFS为7.6个月(95%CI 3.2-15.9)。
  • MET基因拷贝数高(≥10 vs <10)患者ORR有升高趋势。
  • 14例(44%)发生≥3级治疗中出现的不良事件,最常见为肺炎(n=3,9%)。
  • 最终锁库时20例(63%)死亡,中位OS为20.7个月(95%CI 9.9-34.8)。

关键数值与推荐

  • MET基因扩增定义为NGS检测后进展活检标本中MET拷贝数/肿瘤倍性≥4。
  • MET基因拷贝数高定义为≥10,低定义为<10。

临床怎么用

  • 对于一线奥希替尼进展后经NGS确认MET扩增的EGFR突变晚期NSCLC患者,可考虑奥希替尼联合赛沃替尼治疗。
  • 治疗期间需监测肺炎等≥3级不良事件。
  • MET基因拷贝数≥10可能提示更高缓解概率,但需进一步验证。

局限性

  • 样本量小(32例),结果需更大样本验证。
  • ORR置信区间为80%CI,非传统95%CI。
  • 探索性生物标志物分析未报告统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The ORCHARD (NCT03944772) study was conducted to characterize resistance mechanisms and identify optimal treatments after progressive disease (PD) on first-line osimertinib. We report results from the osimertinib plus savolitinib module. METHODS: Patients with EGFR-mutated NSCLC with PD on first-line osimertinib with MET gene amplification (≥4 copies of MET over tumor ploidy) per next-generation sequencing of a post-progression biopsy received osimertinib plus savolitinib. Primary end point was investigator-assessed objective response rate (ORR). Secondary end points included progression-free survival, duration of response, overall survival, and safety. Correlation of ORR with baseline molecular alterations was an exploratory analysis. RESULTS: A total of 32 patients were enrolled; all had tumors with MET amplification. At primary analysis cutoff (January 2023), confirmed ORR was 47% (80% confidence interval [CI]: 34-60). Median duration of response was 14.5 months (95% CI: 5.6-18.7). Median progression-free survival was 7.6 months (95% CI: 3.2-15.9). There was a trend toward increased ORR in patients with high MET gene copy number (≥10 versus <10). Furthermore, 14 patients (44%) had grade 3 or higher treatment-emergent adverse events; most often pneumonia (n = 3; 9%). At final database lock (May 2024), 20 patients (63%) had died; median overall survival was 20.7 months (95% CI: 9.9-34.8). CONCLUSIONS: Osimertinib plus savolitinib demonstrated encouraging clinical benefit in patients with EGFR-mutated advanced NSCLC and MET amplification after PD on first-line osimertinib. Safety was consistent with profiles of the individual drugs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Le X, Baik C, Cho BC, et al. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025. PMID: 41130408. doi:10.1016/j.jtho.2025.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。